Leaving aside the problem of diagnosis, intraventricular haemorrhage is a common condition, of major importance only if it is associated with subsequent handicap. Parenchymal extension4 and posthaemorrhagic ventricular dilation5 have both been suggested to be the most important factors predisposing to adverse outcome, but no infant in this study was reported to have had either of these complications, and therefore the question of whether vitamin E prevents major haemorrhage and possible handicap remains unanswered. In addition, there is evidence from Hittner et alf that intraventricular haemorrhage was actually more common in infants receiving vitamin E supplements. In a double blind clinical study of the efficacy of large dose oral vitamin E .given early to very low birthweight babies to prevent retrolental fibroplasia, more infants in the treatment group developed intraventricular haemorrhage, and, more specifically, twice as many infants sustained intraparenchymal haemorrhage in the vitamin E group than in the controls.
I understand that the Manchester group now intend to conduct a larger controlled study, and we must await further results before accepting that there is a protective effect of vitamin E against intraventricular haemorrhage. SIR,-At first glance the findings of Dr Malcolm L Chiswick and others seem surprising, in that high dosage of vitamin E may be associated with impaired primary haemostasis for two reasons. Firstly, it has been shown to reduce the ability of normal adult platelets to aggregate.' It was estimated that at a plasma concentration of about 70 ,umol/l (3 mg/100 ml), in practice the highest concentration achievable by oral supplementation and yet lower than the peak concentrations found in some of the parenterally treated babies, collagen induced aggregation would be reduced by up to half. Secondly, it has been observed that neonatal plasma has a reduced capacity to generate prostacyclin (PGI2) in vitro, and that exogenous vitamin E, albeit at a concentration five times that found in the plasma of the Manchester babies, would restore PGI2 generation to normal adult concentrations.2 In a healthy adult volunteer we have recently shown that after three days of ingesting DL-c-tocopheryl acetate, 20 mg/kg body weight per day, the urinary excretion of 6-keto PGFI,,, a stable degradation product of PGI,, was increased from a mean of 96-2 (SE 4-42) fmol/mol creatinine to fmol/mol creatinine (p <002).
M I LEVENE
Although confirmation is required in other subjects, this result suggests that vitamin E at these pharmacological dosages may promote PGI2 production in vivo.
In the light of this it would be premature to assume that the very wide safety margin of vitamin E administration in older subjects holds true in the perinatal period. It is, therefore, important to document the occurrence of theoretical complications such as patent ductus arteriosus or pathological bleeding in babies thus treated. We would be interested to learn if such problems were encountered in the Manchester study.
C M TAYLOR SIR,-We agree with Dr Levene that the absence of echoes from within the ventricles does not exclude the presence therein of liquid blood. Although ventricular asymmetry may be observed in the acute phase of intraventricular haemorrhage we do not feel it is specific for that condition. Our criteria for the diagnosis of subependymal and intraventricular haemorrhage are similar to those of other investigators who use the designation of "grade 1" to denote subependymal haemorrhage and grades 2-4 for intraventricular haemorrhage manifest as echogenecity within the ventricles. We chose for simplicity to lump together grades 2, 3, and 4. In the control group four of the nine babies who suffered intraventricular haemorrhage had non-progressive ventricular dilatation (grade 3; n=2) or extension of the haemorrhage from the ventricles into the brain parenchyma (grade 4; n = 2; both died). In the babies receiving vitamin E supplements one of the three with intraventricular haemorrhage had non-progressive ventricular dilatation (grade 3).
The preliminary results of our study must not be dismissed on the basis of comparisons with other investigations where vitamin E was given to premature babies to prevent retrolental fibroplasia and where the mortality or the prevalence of intraventricular haemorrhage was reported. Important variables include the
